Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DKK1 | O94907 | 3/20 | 0.55 |
| ▸ | PKM | P14618 | 2/20 | 0.45 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.44 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.44 |
| ▸ | FAAH | O00519 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SLC6A7 | Q99884 | 2/20 | 0.43 |
| ▸ | SORD | Q00796 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 3/20 | 0.42 |
| ▸ | GBA1 | P04062 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4536981 | 0.89 | DKK1 (0.55) | DKK1PKMDGAT1HCAR2FAAH | |
| SCHEMBL4522804 | 0.89 | DKK1 (0.60) | DKK1PKMDGAT1HCAR2FAAH | |
| SCHEMBL4535156 | 0.86 | DKK1 (0.60) | DKK1PKMDGAT1HCAR2FAAH | |
| SCHEMBL3651342 | 0.86 | DKK1 (0.57) | DKK1PKMDGAT1HCAR2FAAH | |
| SCHEMBL4537288 | 0.86 | DKK1 (0.57) | DKK1PKMDGAT1HCAR2FAAH | |
| SCHEMBL3653482 | 0.84 | PKM (0.61) | DKK1PKMSLC6A7GBA1 | |
| SCHEMBL4534319 | 0.84 | DKK1 (0.55) | DKK1FAAHRAB9ASLC6A7CA9 | |
| SCHEMBL3698714 | 0.84 | DKK1 (0.54) | DKK1PKMDGAT1HCAR2FAAH | |
| SCHEMBL3644943 | 0.83 | DKK1 (0.74) | DKK1SORDPIK3CA | |
| SCHEMBL4538921 | 0.83 | DKK1 (0.59) | DKK1DGAT1HCAR2FAAHCA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090054392-A1 | NAPHTHYLPYRIMIDINE, NAPHTHYLPYRAZINE AND NAPHTHYLPYRIDAZINE ANALOGS AND THEIR USE AS AGONISTS OF THE WNT-BETA-CATENIN CELLULAR MESSAGING SYSTEM | WYETH (US) | 2009-02-26 | — | — | US | claimed |
| US-20090054392-A1 | NAPHTHYLPYRIMIDINE, NAPHTHYLPYRAZINE AND NAPHTHYLPYRIDAZINE ANALOGS AND THEIR USE AS AGONISTS OF THE WNT-BETA-CATENIN CELLULAR MESSAGING SYSTEM | WYETH (US) | 2009-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054392-A1 | NAPHTHYLPYRIMIDINE, NAPHTHYLPYRAZINE AND NAPHTHYLPYRIDAZINE ANALOGS AND THEIR USE AS AGONISTS OF THE WNT-BETA-CATENIN CELLULAR MESSAGING SYSTEM | WNT1, CTNNB1, WNT3A | DKK1 9/4885PKM 2447/4885DGAT1 2165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.